TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.
about
Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosisMarine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Death receptor-ligand systems in cancer, cell death, and inflammationFADD regulates NF-κB activation and promotes ubiquitination of cFLIPL to induce apoptosisSilencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemiaActivation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death.Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency.Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer.Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cellsPrognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression.TRAIL in cancer therapy: present and future challenges.Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis.Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker.Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine.Targeting cell death in tumors by activating caspases.The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious DiseasesCell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.Apoptosis and colorectal cancer.Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice.Mechanisms of resistance to TRAIL-induced apoptosis in cancer.A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.NOXA as critical mediator for drug combinations in polychemotherapy.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.How to target apoptosis signaling pathways for the treatment of pediatric cancersSorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related ProteinsEnhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Absence of TNF-α enhances inflammatory response in the newborn lung undergoing mechanical ventilation.
P2860
Q24670288-AF9CEC58-1E6A-413F-AF3A-B0D71453220FQ26859211-6F26C9B3-01A8-4F60-B8C9-37E6AFE197E1Q26865568-55773BB1-6FAC-4172-B9EE-D30D8C18C525Q28389564-88E43729-7C4F-4ED8-8D71-09AB5E45FF19Q28541221-7B68FD73-BC01-4E1D-90A5-1D2168590A4BQ33564264-287131FE-D1D9-4EDF-BCF8-337B61137017Q33625907-E6647A9B-EF2A-4DBA-8184-0C860D602DDBQ33637916-310C94FE-33DE-46B6-9E1B-C0E1F3BF3403Q33676532-7663C817-15F1-4D1D-8799-88A9D98553D9Q33695003-7D1015CD-82B9-443B-9F77-F5C1BA1764A2Q33721556-CCB15BF1-6D8E-49EF-912A-8B5B700B268DQ33783162-DACF6985-4B6E-43F0-9428-27EFA14C9188Q33959522-1EFD9780-80F5-4E4C-B1D3-358CC9A6C6D0Q34023467-AD7C20A5-FFFB-470F-A48A-22EDF946CF02Q34291312-E8FDCFDD-8778-4127-950A-B469AE5E40B4Q34541614-5FBCF622-2788-4EF9-8298-B188164760BCQ34546374-CBC386D8-AD7D-48C0-8992-F5298FE1E88EQ34560200-3689BBD0-1961-4D80-B41F-09D204D5BD8BQ34564468-A3C8F63A-102D-4727-A130-E8064EF8C698Q34809370-721378DD-B31D-4E0C-9262-E87DDBF8D246Q34929094-402C2C71-226D-49D7-A5DE-9E772E565BA3Q35023172-448962E1-293D-4C34-AA8D-88353B5C4312Q35058822-1913F979-F812-40D4-8329-240511E157FDQ35172090-1040D756-BFA0-40BA-8AAF-9504F3A79842Q35635562-194B1E31-4BA8-4270-AA3A-95C45E607D8FQ35853714-9F64E29A-2EE7-4593-9282-918A43C26346Q35909089-E0094630-967F-4889-A7D3-7BA32A4DF408Q35915905-CFDEA7D7-9EFA-45A4-8860-A0AAD3955797Q35950948-0D1DDD2B-3669-4DDE-A029-C0B92BC14FF9Q35954258-6D983782-75E4-471C-ACB9-DF377333A671Q35967192-6EB2969E-8BC6-42E8-B67A-423124B111E9Q36071973-093600DC-06B1-4C12-AAAA-030469B87C65Q36365504-718ED517-AAC4-4FBE-88DE-28480FA0CD2EQ36508944-36F86736-74DF-411E-A6E9-691327627829Q36610528-C6FAD2B3-00F3-44D0-9441-BB399B10BC8BQ36629288-53B0BC8B-C740-4786-BF0B-5ED666E58063Q36692259-75DCCC9D-B030-4BC5-8D36-DB3E76D9FFF7Q36709220-0CB985BD-72AF-4DFF-A713-E4FE563D8574Q36731174-3926F831-65A9-41D5-B69D-6E497AA6ED25Q36976617-44A04BEC-B7E0-4B99-B648-416D1DA14655
P2860
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@en
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@nl
type
label
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@en
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@nl
prefLabel
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@en
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@nl
P2860
P50
P356
P1433
P1476
TRAIL induced survival and pro ...... optosis mediated by NF-kappaB.
@en
P2093
Irene Schmid
John Hiscott
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206520
P407
P577
2003-06-01T00:00:00Z